drugset / Trial / NCT00470314

Therapeutic Efficacy of L-Ornithine L-Aspartate Infusion in Patients With Acute Liver Failure

NCT00470314 ↗

Phase 2 Unknown 150 enrolled All India Institute of Medical Sciences
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of the study is to determine whether L-Ornithine L-Aspartate infusion improves the survival of patients with acute liver failure.

Timeline

Start
2005-01
Primary completion
—
Completion
2007-05

Outcome

Missed primary endpoint

paper There was no reduction in mortality with LOLA treatment (mortality: 33.3% in placebo and 42.4% in LOLA; relative risk of death 1.27; 95% CI: 0.88-1.85; P = .204). PMID 19505424 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject L-ornithine L-aspartate Other / unclassified 30 g —

Indications